Drug-drug Interaction Study With AZD5335 and Itraconazole in Participants With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
← catalyst calendarNCT07402915 · readout in 421 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
24estimated
Sites
9
Countries
Georgia, Ireland, Portugal +1
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-01-26 | actual | When the study began enrolling |
| Primary completion | 2027-10-15 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-10-15 | estimated | The whole study's end, after follow-up |
| First posted | 2026-02-11 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-07 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Fallopian Tube Cancer
- Ovarian Cancer
- Primary Peritoneal
Interventions
- Drug: AZD5335 — also filed as AZ14170132
- Drug: Itraconazole
Primary outcomes
what the primary-completion date above is the date OFArea under curve from time 0 to time 17 days (AUC0-17days)
measured Cycle 2 and Cycle 3 (each cycle is of 21 days)
Maximum plasma drug concentration (Cmax)
measured Cycle 2 and Cycle 3 (each cycle is of 21 days)
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed